S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68

Covetrus (CVET) Stock Forecast, Price & News

+1.69 (+9.38%)
(As of 05/20/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
7.28 million shs
Average Volume
1.11 million shs
Market Capitalization
$2.75 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive CVET News and Ratings via Email

Sign-up to receive the latest news and ratings for Covetrus and its competitors with MarketBeat's FREE daily newsletter.

Covetrus logo

About Covetrus

Covetrus, Inc., together with its subsidiaries, operates as an animal-health technology and services company. It engages in the sale of animal-health consumable products, including proprietary and Covetrus branded products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, parasiticides, and vitamins and supplements to wholesale and retail customers. The company also offers value-added solutions, such as inventory management and e-commerce, as well as continuing education services for practitioners. In addition, it provides practice management software, data-driven applications, client communications tools, and related services to increase staff efficiency and enhance business health; and solutions that integrate with its software platforms, including client communication services, reminders, data backup services, hardware sales and support, and credit card processing services for veterinary practitioners and animal-health clinics. Further, the company engages in the distribution of finished goods pharmacy and specialty pharmaceutical compounding products, as well as offers shipping, manufacturer incentives, service fees, and data integration and support services. It serves animal-health and veterinary practices, and clinics in the companion-animal, equine, and large-animal markets primarily in North America, Europe, and the Asia Pacific. The company was formerly known as HS Spinco, Inc. Covetrus, Inc. was incorporated in 2018 and is headquartered in Portland, Maine.


See More Headlines

Industry, Sector and Symbol

Drug stores & proprietary stores
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$4.58 billion
Cash Flow
$2.39 per share
Book Value
$10.96 per share


Net Income
$-54 million
Pretax Margin




Free Float
Market Cap
$2.75 billion
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.89 out of 5 stars

Computer And Technology Sector

480th out of 919 stocks

Drug Stores & Proprietary Stores Industry

4th out of 9 stocks

Analyst Opinion: 2.2Community Rank: 3.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Covetrus (NASDAQ:CVET) Frequently Asked Questions

Is Covetrus a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Covetrus in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Covetrus stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CVET, but not buy additional shares or sell existing shares.
View analyst ratings for Covetrus
or view top-rated stocks.

Are investors shorting Covetrus?

Covetrus saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 3,240,000 shares, an increase of 21.8% from the April 15th total of 2,660,000 shares. Based on an average trading volume of 756,100 shares, the days-to-cover ratio is presently 4.3 days. Approximately 3.1% of the company's stock are short sold.
View Covetrus' Short Interest

When is Covetrus' next earnings date?

Covetrus is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Covetrus

How were Covetrus' earnings last quarter?

Covetrus, Inc. (NASDAQ:CVET) announced its quarterly earnings data on Thursday, May, 5th. The company reported $0.25 EPS for the quarter, beating the consensus estimate of $0.22 by $0.03. The company earned $1.15 billion during the quarter, compared to analysts' expectations of $1.15 billion. Covetrus had a positive trailing twelve-month return on equity of 1.92% and a negative net margin of 0.87%. The company's revenue for the quarter was up 4.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.16 EPS.
View Covetrus' earnings history

What price target have analysts set for CVET?

6 brokerages have issued 1 year target prices for Covetrus' shares. Their forecasts range from $16.00 to $30.00. On average, they anticipate Covetrus' stock price to reach $24.50 in the next year. This suggests a possible upside of 24.3% from the stock's current price.
View analysts' price targets for Covetrus
or view top-rated stocks among Wall Street analysts.

Who are Covetrus' key executives?
Covetrus' management team includes the following people:
  • Mr. Benjamin Wolin, Pres, CEO & Director (Age 46, Pay $1.02M) (LinkedIn Profile)
  • Mr. Matthew J. Foulston, Exec. VP & Global CFO (Age 57, Pay $624.66k)
  • Ms. Georgina Wraight, Exec. VP & Pres of Global Technology Solutions (Age 47, Pay $563.4k)
  • Mr. Dustin k. Finer, Chief Admin. Officer (Age 52, Pay $552.67k) (LinkedIn Profile)
  • Mr. Matthew Malenfant, Chief Commercial Officer (Age 60, Pay $533.62k)
  • Ms. Rebecca Kidd, Head of Operations & Operational Excellence (Age 53)
  • Mr. Andrew B. Coxhead, VP, Corp. Controller & Chief Accounting Officer (Age 53)
  • Mr. Nicholas Michael Jansen, VP of Investor Relations
  • Ms. Ditte Marstrand Wulf, Global Chief HR Officer (Age 51)
  • Mr. Russell Cooke, Sr. VP & Operational CFO (Age 56)
What is Benjamin Wolin's approval rating as Covetrus' CEO?

25 employees have rated Covetrus CEO Benjamin Wolin on Glassdoor.com. Benjamin Wolin has an approval rating of 89% among Covetrus' employees.

What other stocks do shareholders of Covetrus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Covetrus investors own include Pfizer (PFE), NVIDIA (NVDA), Advanced Micro Devices (AMD), AT&T (T), Activision Blizzard (ATVI), Boeing (BA), Chegg (CHGG), Enphase Energy (ENPH), Enterprise Products Partners (EPD) and Livongo Health (LVGO).

What is Covetrus' stock symbol?

Covetrus trades on the NASDAQ under the ticker symbol "CVET."

Who are Covetrus' major shareholders?

Covetrus' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (11.83%), Vanguard Group Inc. (8.28%), Wellington Management Group LLP (6.00%), JPMorgan Chase & Co. (3.55%), Freshford Capital Management LLC (2.78%) and State Street Corp (2.76%). Company insiders that own Covetrus stock include Anthony C Jr Providenti, Benjamin Wolin, David Stuart Hinton, Dustin Finer, Edward Mcnamara, Georgina Wraight, Herbert Virgin, Laura J Phillips, Michael Ellis and Timothy Ludlow.
View institutional ownership trends for Covetrus

Which major investors are selling Covetrus stock?

CVET stock was sold by a variety of institutional investors in the last quarter, including Schf GPE LLC, Frontier Capital Management Co. LLC, Goldman Sachs Group Inc., Allianz Asset Management GmbH, Palisade Capital Management LLC NJ, Madison Asset Management LLC, Freshford Capital Management LLC, and Bank of New York Mellon Corp. Company insiders that have sold Covetrus company stock in the last year include Benjamin Wolin, Dustin Finer, Herbert Virgin, Laura J Phillips, Michael Ellis, and Timothy Ludlow.
View insider buying and selling activity for Covetrus
or view top insider-selling stocks.

Which major investors are buying Covetrus stock?

CVET stock was purchased by a variety of institutional investors in the last quarter, including Select Equity Group L.P., Fort Washington Investment Advisors Inc. OH, Dimensional Fund Advisors LP, Wellington Management Group LLP, Kovitz Investment Group Partners LLC, Vanguard Group Inc., Royce & Associates LP, and Charles Schwab Investment Management Inc..
View insider buying and selling activity for Covetrus
or or view top insider-buying stocks.

How do I buy shares of Covetrus?

Shares of CVET can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Covetrus' stock price today?

One share of CVET stock can currently be purchased for approximately $19.71.

How much money does Covetrus make?

Covetrus has a market capitalization of $2.75 billion and generates $4.58 billion in revenue each year. The company earns $-54 million in net income (profit) each year or ($0.300010) on an earnings per share basis.

How many employees does Covetrus have?

Covetrus employs 5,710 workers across the globe.

What is Covetrus' official website?

The official website for Covetrus is www.henryscheinvet.com.

How can I contact Covetrus?

Covetrus' mailing address is 7 CUSTOM HOUSE STREET, PORTLAND ME, 04101. The company can be reached via phone at (888) 280-2221 or via email at [email protected].

This page was last updated on 5/21/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.